Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) will present clinical data from its tegoprubart program for kidney transplant patients at the American ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE